{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:13:13Z","timestamp":1784232793295,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UM1 TR004538"],"award-info":[{"award-number":["UM1 TR004538"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11606-024-09081-2","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:01:44Z","timestamp":1729090904000},"page":"871-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rising Prevalence of Obesity and Primary Hyperaldosteronism: Co-incidence or Connected Circumstances Leading to Hypertension? A Narrative Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-2799","authenticated-orcid":false,"given":"Shweta","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houry","family":"Puzantian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond R.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"issue":"15","key":"9081_CR1","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMc1710026","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Reitsma MB, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries. The New England journal of medicine. Oct 12 2017;377(15):1496-7. https:\/\/doi.org\/10.1056\/NEJMc1710026","journal-title":"The New England journal of medicine."},{"issue":"3","key":"9081_CR2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/oxfordjournals.aje.a008733","volume":"143","author":"D Gallagher","year":"1996","unstructured":"Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? American journal of epidemiology. Feb 1 1996;143(3):228-39. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a008733","journal-title":"American journal of epidemiology."},{"issue":"10431","key":"9081_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","volume":"403","author":"Collaboration NCDRF","year":"2024","unstructured":"Collaboration NCDRF. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. Mar 16 2024;403(10431):1027-1050. https:\/\/doi.org\/10.1016\/S0140-6736(23)02750-2","journal-title":"Lancet"},{"key":"9081_CR4","unstructured":"Center for Disese Control - Adult Obesity Facts. 2023."},{"key":"9081_CR5","doi-asserted-by":"publisher","first-page":"706978","DOI":"10.3389\/fendo.2021.706978","volume":"12","author":"X Lin","year":"2021","unstructured":"Lin X, Li H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne). 2021;12:706978. https:\/\/doi.org\/10.3389\/fendo.2021.706978","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"9081_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/01.cir.67.5.968","volume":"67","author":"HB Hubert","year":"1983","unstructured":"Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. May 1983;67(5):968-77. https:\/\/doi.org\/10.1161\/01.cir.67.5.968","journal-title":"Circulation."},{"issue":"10","key":"9081_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","volume":"286","author":"AH Mokdad","year":"2001","unstructured":"Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. Jama. Sep 12 2001;286(10):1195-200. https:\/\/doi.org\/10.1001\/jama.286.10.1195","journal-title":"Jama."},{"issue":"38","key":"9081_CR8","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.1038\/sj.onc.1207751","volume":"23","author":"EE Calle","year":"2004","unstructured":"Calle EE, Thun MJ. Obesity and cancer. Oncogene. Aug 23 2004;23(38):6365-78. https:\/\/doi.org\/10.1038\/sj.onc.1207751","journal-title":"Oncogene."},{"issue":"1","key":"9081_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1161\/STROKEAHA.111.639922","volume":"44","author":"WN Kernan","year":"2013","unstructured":"Kernan WN, Inzucchi SE, Sawan C, Macko RF, Furie KL. Obesity: a stubbornly obvious target for stroke prevention. Stroke. Jan 2013;44(1):278-86. https:\/\/doi.org\/10.1161\/STROKEAHA.111.639922","journal-title":"Stroke."},{"issue":"2","key":"9081_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/osp4.629","volume":"9","author":"S Nawaz","year":"2023","unstructured":"Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, Sinha S. Obesity and chronic kidney disease: A current review. Obes Sci Pract. Apr 2023;9(2):61-74. https:\/\/doi.org\/10.1002\/osp4.629","journal-title":"Obes Sci Pract."},{"key":"9081_CR11","unstructured":"A Snapshot: Diabetes In The United States."},{"key":"9081_CR12","unstructured":"Hypertension Cascade: Hypertension Prevalence, Treatment and Control Estimates Among U.S. Adults Aged 18 Years and Older Applying the Criteria from the American College of Cardiology and American Heart Association\u2019s 2017 Hypertension Guideline\u2014NHANES 2015\u20132018."},{"issue":"1","key":"9081_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12049","volume":"15","author":"L Landsberg","year":"2013","unstructured":"Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, Sowers J. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). Jan 2013;15(1):14-33. https:\/\/doi.org\/10.1111\/jch.12049","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"1","key":"9081_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/HYPERTENSIONAHA.117.09980","volume":"71","author":"JL Faulkner","year":"2018","unstructured":"Faulkner JL, Belin de Chantemele EJ. Sex Differences in Mechanisms of Hypertension Associated With Obesity. Hypertension. Jan 2018;71(1):15-21. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09980","journal-title":"Hypertension."},{"issue":"4","key":"9081_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2009.1060","volume":"302","author":"JP Forman","year":"2009","unstructured":"Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk factors associated with incident hypertension in women. Jama. Jul 22 2009;302(4):401-11. https:\/\/doi.org\/10.1001\/jama.2009.1060","journal-title":"Jama."},{"issue":"2","key":"9081_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0091-7435(87)90087-9","volume":"16","author":"RJ Garrison","year":"1987","unstructured":"Garrison RJ, Kannel WB, Stokes J, 3rd, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. Mar 1987;16(2):235-51. https:\/\/doi.org\/10.1016\/0091-7435(87)90087-9","journal-title":"Prev Med."},{"key":"9081_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.0954-6820.1987.tb05925.x","volume":"723","author":"M Higgins","year":"1988","unstructured":"Higgins M, Kannel W, Garrison R, Pinsky J, Stokes J, 3rd. Hazards of obesity--the Framingham experience. Acta Med Scand Suppl. 1988;723:23-36. https:\/\/doi.org\/10.1111\/j.0954-6820.1987.tb05925.x","journal-title":"Acta Med Scand Suppl."},{"issue":"20","key":"9081_CR18","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1056\/NEJMoa1010112","volume":"365","author":"M Juonala","year":"2011","unstructured":"Juonala M, Magnussen CG, Berenson GS, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. The New England journal of medicine. Nov 17 2011;365(20):1876-85. https:\/\/doi.org\/10.1056\/NEJMoa1010112","journal-title":"The New England journal of medicine."},{"issue":"3","key":"9081_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/oby.2000.32","volume":"8","author":"IL Mertens","year":"2000","unstructured":"Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. May 2000;8(3):270-8. https:\/\/doi.org\/10.1038\/oby.2000.32","journal-title":"Obes Res."},{"issue":"1","key":"9081_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/M20-1758","volume":"173","author":"Funder JW","year":"2020","unstructured":"Funder JW. Primary Aldosteronism: At the Tipping Point. Annals of internal medicine. Jul 7 2020;173(1):65-66. https:\/\/doi.org\/10.7326\/M20-1758","journal-title":"Annals of internal medicine."},{"issue":"8917","key":"9081_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/s0140-6736(94)93003-1","volume":"344","author":"RD Gordon","year":"1994","unstructured":"Gordon RD. Mineralocorticoid hypertension. Lancet. Jul 23 1994;344(8917):240-3. https:\/\/doi.org\/10.1016\/s0140-6736(94)93003-1","journal-title":"Lancet."},{"issue":"6","key":"9081_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.7326\/0003-4819-66-6-1079","volume":"66","author":"NM Kaplan","year":"1967","unstructured":"Kaplan NM. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Annals of internal medicine. Jun 1967;66(6):1079-90. https:\/\/doi.org\/10.7326\/0003-4819-66-6-1079","journal-title":"Annals of internal medicine."},{"issue":"8","key":"9081_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/L20-1097","volume":"173","author":"A Vaidya","year":"2020","unstructured":"Vaidya A, Brown JM, Carey RM, Siddiqui M, Williams GH. The Unrecognized Prevalence of Primary Aldosteronism. Annals of internal medicine. Oct 20 2020;173(8):683. https:\/\/doi.org\/10.7326\/L20-1097","journal-title":"Annals of internal medicine."},{"issue":"14","key":"9081_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"Monticone S, Burrello J, Tizzani D, et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. Journal of the American College of Cardiology. Apr 11 2017;69(14):1811-1820. https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052","journal-title":"Journal of the American College of Cardiology."},{"issue":"7","key":"9081_CR25","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1210\/jc.2016-1472","volume":"101","author":"SC Kayser","year":"2016","unstructured":"Kayser SC, Dekkers T, Groenewoud HJ, et al. Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. Jul 2016;101(7):2826-35. https:\/\/doi.org\/10.1210\/jc.2016-1472","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"9081_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12902-020-00654-w","volume":"20","author":"W Manosroi","year":"2020","unstructured":"Manosroi W, Atthakomol P. High body fat percentage is associated with primary aldosteronism: a cross-sectional study. BMC Endocr Disord. Nov 23 2020;20(1):175. https:\/\/doi.org\/10.1186\/s12902-020-00654-w","journal-title":"BMC Endocr Disord."},{"issue":"2","key":"9081_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. Aug 2006;48(2):239-45. https:\/\/doi.org\/10.1161\/01.HYP.0000231338.41548.fc","journal-title":"Hypertension."},{"issue":"2","key":"9081_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"Fallo F, Veglio F, Bertello C, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. Feb 2006;91(2):454-9. https:\/\/doi.org\/10.1210\/jc.2005-1733","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"9081_CR29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/01.HYP.0000253258.36141.c7","volume":"49","author":"S Kidambi","year":"2007","unstructured":"Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. Mar 2007;49(3):704-11. https:\/\/doi.org\/10.1161\/01.HYP.0000253258.36141.c7","journal-title":"Hypertension."},{"issue":"3","key":"9081_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/HYPERTENSIONAHA.110.168872","volume":"58","author":"A Nguyen Dinh Cat","year":"2011","unstructured":"Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, Touyz RM. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension. Sep 2011;58(3):479-88. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.168872","journal-title":"Hypertension."},{"issue":"5","key":"9081_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. May 2012;59(5):1069-78. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.190223","journal-title":"Hypertension."},{"issue":"1","key":"9081_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/jpet.114.221002","volume":"353","author":"FJ Rios","year":"2015","unstructured":"Rios FJ, Neves KB, Nguyen Dinh Cat A, Even S, Palacios R, Montezano AC, Touyz RM. Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes. J Pharmacol Exp Ther. Apr 2015;353(1):27-34. https:\/\/doi.org\/10.1124\/jpet.114.221002","journal-title":"J Pharmacol Exp Ther."},{"issue":"22","key":"9081_CR33","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"AC Huby","year":"2015","unstructured":"Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, Belin de Chantemele EJ. Adipocyte-Derived Hormone Leptin Is a Direct Regulator of Aldosterone Secretion, Which Promotes Endothelial Dysfunction and Cardiac Fibrosis. Circulation. Dec 1 2015;132(22):2134-45. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018226","journal-title":"Circulation."},{"issue":"5","key":"9081_CR34","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/sj.ijo.0803508","volume":"31","author":"S Schinner","year":"2007","unstructured":"Schinner S, Willenberg HS, Krause D, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond). May 2007;31(5):864-70. https:\/\/doi.org\/10.1038\/sj.ijo.0803508","journal-title":"Int J Obes (Lond)."},{"issue":"4","key":"9081_CR35","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","volume":"68","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. Oct 2016;68(4):995-1003. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07806","journal-title":"Hypertension."},{"issue":"11","key":"9081_CR36","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1210\/jc.2007-1088","volume":"92","author":"R Bentley-Lewis","year":"2007","unstructured":"Bentley-Lewis R, Adler GK, Perlstein T, Seely EW, Hopkins PN, Williams GH, Garg R. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab. Nov 2007;92(11):4472-5. https:\/\/doi.org\/10.1210\/jc.2007-1088","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"9081_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. Aug 28 2007;116(9):984-92. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.708537","journal-title":"Circulation."},{"issue":"1","key":"9081_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1532-5415.1981.tb02389.x","volume":"29","author":"K Hiramatsu","year":"1981","unstructured":"Hiramatsu K, Yamada T, Ichikawa K, Izumiyama T, Nagata H. Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc. Jan 1981;29(1):25-30. https:\/\/doi.org\/10.1111\/j.1532-5415.1981.tb02389.x","journal-title":"J Am Geriatr Soc."},{"issue":"7","key":"9081_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/ajh.2012.47","volume":"25","author":"R Sarzani","year":"2012","unstructured":"Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessi-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. American journal of hypertension. Jul 2012;25(7):818-26. https:\/\/doi.org\/10.1038\/ajh.2012.47","journal-title":"American journal of hypertension."},{"issue":"10","key":"9081_CR40","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/hr.2013.45","volume":"36","author":"JN Cooper","year":"2013","unstructured":"Cooper JN, Fried L, Tepper P, et al. Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults. Hypertens Res. Oct 2013;36(10):895-901. https:\/\/doi.org\/10.1038\/hr.2013.45","journal-title":"Hypertens Res."},{"issue":"1","key":"9081_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12902-020-0527-4","volume":"20","author":"P Suwannasrisuk","year":"2020","unstructured":"Suwannasrisuk P, Boonchaya-Anant P, Houngngam N, Udomsawaengsup S, Sunthornyothin S. Changes in plasma aldosterone level after weight loss by bariatric surgery in morbidly obese patients. BMC Endocr Disord. Apr 6 2020;20(1):45. https:\/\/doi.org\/10.1186\/s12902-020-0527-4","journal-title":"BMC Endocr Disord."},{"issue":"2","key":"9081_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/HYPERTENSIONAHA.113.02988","volume":"64","author":"G Seravalle","year":"2014","unstructured":"Seravalle G, Colombo M, Perego P, et al. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients. Hypertension. Aug 2014;64(2):431-7. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02988","journal-title":"Hypertension."},{"issue":"6","key":"9081_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1681\/ASN.2013121258","volume":"25","author":"T Fujita","year":"2014","unstructured":"Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. Journal of the American Society of Nephrology : JASN. Jun 2014;25(6):1148-55. https:\/\/doi.org\/10.1681\/ASN.2013121258","journal-title":"Journal of the American Society of Nephrology : JASN."},{"issue":"2","key":"9081_CR44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","volume":"53","author":"Funder JW","year":"2009","unstructured":"Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. Feb 2009;53(2):286-90. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.119966","journal-title":"Hypertension."},{"issue":"10008","key":"9081_CR45","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. Nov 21 2015;386(10008):2059-2068. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3","journal-title":"Lancet."},{"issue":"9","key":"9081_CR46","first-page":"963","volume":"9","author":"BA Maron","year":"2008","unstructured":"Maron BA, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. Curr Opin Investig Drugs. Sep 2008;9(9):963-9.","journal-title":"Curr Opin Investig Drugs."},{"issue":"1","key":"9081_CR47","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1758-5996-6-90","volume":"6","author":"T Bruder-Nascimento","year":"2014","unstructured":"Bruder-Nascimento T, da Silva MA, Tostes RC. The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):90. https:\/\/doi.org\/10.1186\/1758-5996-6-90","journal-title":"Diabetol Metab Syndr."},{"issue":"4","key":"9081_CR48","doi-asserted-by":"publisher","first-page":"e028146","DOI":"10.1161\/JAHA.122.028146","volume":"12","author":"VC Wu","year":"2023","unstructured":"Wu VC, Chan CK, Chueh JS, et al. Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. Journal of the American Heart Association. Feb 21 2023;12(4):e028146. https:\/\/doi.org\/10.1161\/JAHA.122.028146","journal-title":"Journal of the American Heart Association."},{"issue":"1","key":"9081_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/1570161119666210720120439","volume":"20","author":"A Mares","year":"2022","unstructured":"Mares A, Rodriguez T, Deoker A, Lehker A, Mukherjee D. Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review. Curr Vasc Pharmacol. 2022;20(1):46-51. https:\/\/doi.org\/10.2174\/1570161119666210720120439","journal-title":"Curr Vasc Pharmacol."},{"issue":"2","key":"9081_CR50","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. Feb 2015;65(2):257-63. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04488","journal-title":"Hypertension."},{"issue":"1","key":"9081_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","volume":"12","author":"T Nakamura","year":"2022","unstructured":"Nakamura T, Girerd S, Jaisser F, Barrera-Chimal J. Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl (2011). Apr 2022;12(1):12-18. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.004","journal-title":"Kidney Int Suppl (2011)"},{"issue":"24","key":"9081_CR52","doi-asserted-by":"publisher","first-page":"16633","DOI":"10.1074\/jbc.M109.008748","volume":"284","author":"S Bunda","year":"2009","unstructured":"Bunda S, Wang Y, Mitts TF, Liu P, Arab S, Arabkhari M, Hinek A. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase\/Akt. J Biol Chem. Jun 12 2009;284(24):16633-16647. https:\/\/doi.org\/10.1074\/jbc.M109.008748","journal-title":"J Biol Chem."},{"issue":"2","key":"9081_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1681\/ASN.2020071041","volume":"32","author":"N Ayuzawa","year":"2021","unstructured":"Ayuzawa N, Fujita T. The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury. Journal of the American Society of Nephrology : JASN. Feb 2021;32(2):279-289. https:\/\/doi.org\/10.1681\/ASN.2020071041","journal-title":"Journal of the American Society of Nephrology : JASN."},{"issue":"8","key":"9081_CR54","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/cvr\/cvaa336","volume":"117","author":"JE Hall","year":"2021","unstructured":"Hall JE, Mouton AJ, da Silva AA, Omoto ACM, Wang Z, Li X, do Carmo JM. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Cardiovasc Res. Jul 7 2021;117(8):1859-1876. https:\/\/doi.org\/10.1093\/cvr\/cvaa336","journal-title":"Cardiovasc Res."},{"issue":"9","key":"9081_CR55","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1515\/cclm-2015-1094","volume":"54","author":"GP Rossi","year":"2016","unstructured":"Rossi GP, Ceolotto G, Rossitto G, et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin Chem Lab Med. Sep 1 2016;54(9):1441-50. https:\/\/doi.org\/10.1515\/cclm-2015-1094","journal-title":"Clin Chem Lab Med."},{"issue":"3","key":"9081_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans : A Retrospective Cohort Study. Annals of internal medicine. Mar 2021;174(3):289-297. https:\/\/doi.org\/10.7326\/M20-4873","journal-title":"Annals of internal medicine."},{"issue":"8","key":"9081_CR57","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1210\/jc.2013-4146","volume":"99","author":"V Lim","year":"2014","unstructured":"Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, Young WF, Jr. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab. Aug 2014;99(8):2712-9. https:\/\/doi.org\/10.1210\/jc.2013-4146","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"9081_CR58","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1172\/JCI7840","volume":"104","author":"S Masilamani","year":"1999","unstructured":"Masilamani S, Kim GH, Mitchell C, Wade JB, Knepper MA. Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. The Journal of clinical investigation. Oct 1999;104(7):R19-23. https:\/\/doi.org\/10.1172\/JCI7840","journal-title":"The Journal of clinical investigation."},{"key":"9081_CR59","doi-asserted-by":"publisher","unstructured":"Mattsson C, Young WF, Jr. Primary aldosteronism: diagnostic and treatment strategies. Nature clinical practice Nephrology. Apr 2006;2(4):198\u2013208; quiz, 1 p following 230. https:\/\/doi.org\/10.1038\/ncpneph0151","DOI":"10.1038\/ncpneph0151"},{"issue":"1","key":"9081_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13618","volume":"294","author":"H Schneider","year":"2023","unstructured":"Schneider H, Sarkis AL, Sturm L, et al. Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: The salt CONNtrol trial. J Intern Med. Jul 2023;294(1):47-57. https:\/\/doi.org\/10.1111\/joim.13618","journal-title":"J Intern Med."},{"issue":"5","key":"9081_CR61","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","volume":"42","author":"JE Neter","year":"2003","unstructured":"Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. Nov 2003;42(5):878-84. https:\/\/doi.org\/10.1161\/01.HYP.0000094221.86888.AE","journal-title":"Hypertension."},{"issue":"2","key":"9081_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"ARG Look","year":"2013","unstructured":"Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. The New England journal of medicine. Jul 11 2013;369(2):145-54. https:\/\/doi.org\/10.1056\/NEJMoa1212914","journal-title":"The New England journal of medicine."},{"issue":"9997","key":"9081_CR63","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(15)00075-6","volume":"386","author":"G Mingrone","year":"2015","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. Sep 5 2015;386(9997):964-73. https:\/\/doi.org\/10.1016\/S0140-6736(15)00075-6","journal-title":"Lancet."},{"issue":"7","key":"9081_CR64","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1056\/NEJMc1407393","volume":"371","author":"PR Schauer","year":"2014","unstructured":"Schauer PR, Bhatt DL, Kashyap SR. Bariatric surgery versus intensive medical therapy for diabetes. The New England journal of medicine. Aug 14 2014;371(7):682. https:\/\/doi.org\/10.1056\/NEJMc1407393","journal-title":"The New England journal of medicine."},{"issue":"1","key":"9081_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/jhh.2013.42","volume":"28","author":"JB Byrd","year":"2014","unstructured":"Byrd JB, Brook RD. A critical review of the evidence supporting aldosterone in the etiology and its blockade in the treatment of obesity-associated hypertension. J Hum Hypertens. Jan 2014;28(1):3-9. https:\/\/doi.org\/10.1038\/jhh.2013.42","journal-title":"J Hum Hypertens."},{"issue":"6","key":"9081_CR66","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. European heart journal. Feb 10 2022;43(6):474-484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"European heart journal."},{"issue":"12","key":"9081_CR67","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2215\/CJN.0000000000000265","volume":"18","author":"RR Townsend","year":"2023","unstructured":"Townsend RR. Blocking Aldosterone Synthesis: Whose BrigHTN Idea Was That? Clinical journal of the American Society of Nephrology : CJASN. Dec 1 2023;18(12):1631-1633. https:\/\/doi.org\/10.2215\/CJN.0000000000000265","journal-title":"Clinical journal of the American Society of Nephrology : CJASN."},{"issue":"5","key":"9081_CR68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. The New England journal of medicine. Feb 2 2023;388(5):395-405. https:\/\/doi.org\/10.1056\/NEJMoa2213169","journal-title":"The New England journal of medicine."},{"issue":"6","key":"9081_CR69","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.kint.2024.03.017","volume":"105","author":"M Nangaku","year":"2024","unstructured":"Nangaku M. SGLT2 inhibitor: 2-way superstar in nephrology? Kidney international. Jun 2024;105(6):1176-1177. https:\/\/doi.org\/10.1016\/j.kint.2024.03.017","journal-title":"Kidney international."},{"key":"9081_CR70","doi-asserted-by":"publisher","first-page":"100502","DOI":"10.1016\/j.ajpc.2023.100502","volume":"14","author":"ED Michos","year":"2023","unstructured":"Michos ED, Bakris GL, Rodbard HW, Tuttle KR. Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Am J Prev Cardiol. Jun 2023;14:100502. https:\/\/doi.org\/10.1016\/j.ajpc.2023.100502","journal-title":"Am J Prev Cardiol."},{"issue":"9","key":"9081_CR71","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab. Sep 2021;23(9):2116-2124. https:\/\/doi.org\/10.1111\/dom.14451","journal-title":"Diabetes Obes Metab."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09081-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-024-09081-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-024-09081-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:12:41Z","timestamp":1764267161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-024-09081-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9081"],"URL":"https:\/\/doi.org\/10.1007\/s11606-024-09081-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"SB: Royalty from UpToDate; Advisory board member to Novartis, Calliditas, Vera, Travere\u00a0and Daxor; Research funding from Novonordisk, AstraZeneca\u00a0and Bayer; Speaker bureau: Home dialysis university.HP: Intra-mural Institutional research grant.RRT: Consultant to Medtronic, Regeneron, AstraZeneca, Bard, Orchestra Backbeat; DSMB member AXIO, NOVARTIS, NIH; Royalty from UpToDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}